The estimated Net Worth of Jules A. Musing is at least $391 Tysiąc dollars as of 18 August 2022. Mr. Musing owns over 1,984 units of TherapeuticsMD Inc stock worth over $7,151 and over the last 13 years he sold TXMD stock worth over $201,840. In addition, he makes $182,508 as Independent Director at TherapeuticsMD Inc.
Sign up
Mr. Musing TXMD stock SEC Form 4 insiders trading
Jules has made over 8 trades of the TherapeuticsMD Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 1,984 units of TXMD stock worth $3,527 on 18 August 2022.
The largest trade he's ever made was exercising 96,864 units of TherapeuticsMD Inc stock on 10 August 2021 worth over $172,215. On average, Jules trades about 4,902 units every 103 days since 2012. As of 18 August 2022 he still owns at least 4,022 units of TherapeuticsMD Inc stock.
You can see the complete history of Mr. Musing stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jules Musing biography
Jules A. Musing serves as Independent Director of the Company. In the course of Mr. Musing’s 37-year career in the pharmaceutical and biotechnology industry, specifically at Johnson & Johnson and its affiliates, he has been responsible for the worldwide licensing and acquisition of pharmaceutical and biotechnology products and technologies and the establishment of strategic alliances. This included the establishment of new scientific, technology and product collaborations in various therapeutic areas, the negotiation of licensing and alliance agreements with biotechnology and pharmaceutical companies worldwide, and the partnering, spin-out and out-licensing of company pharmaceutical and biotechnology assets. Prior to moving into those roles, Mr. Musing was Vice President Marketing International for the Janssen Pharmaceutical Group of Companies Worldwide from March 1982 to December 1984; President of Pitman-Moore, Inc., a U.S.-based Johnson & Johnson company from January 1985 to June 1987; Managing Director of Janssen Pharmaceutical in Portugal from July 1987 to March 1990; President of Serono, Inc. in the United States and Executive Vice President with responsibilities for North and South America from April 1990 to January 1993; Member of the board of directors of Ortho Biotech, Inc. from January 1993 to October 1999; and Managing Director of Ortho Biotech in France (a Johnson & Johnson affiliate) from October 1999 to January 2003. Mr. Musing received his Master’s Degree in Biological Sciences from the University of Brussels (Belgium) and his Graduate Degree in Economics and Financial Sciences from the University of Antwerp (Belgium).
What is the salary of Jules Musing?
As the Independent Director of TherapeuticsMD Inc, the total compensation of Jules Musing at TherapeuticsMD Inc is $182,508. There are 11 executives at TherapeuticsMD Inc getting paid more, with John Milligan having the highest compensation of $1,440,640.
How old is Jules Musing?
Jules Musing is 72, he's been the Independent Director of TherapeuticsMD Inc since 2017. There are 1 older and 25 younger executives at TherapeuticsMD Inc. The oldest executive at TherapeuticsMD Inc is Tommy Thompson, 78, who is the Independent Chairman of the Board.
What's Jules Musing's mailing address?
Jules's mailing address filed with the SEC is 951 YAMATO ROAD, SUITE 220, BOCA RATON, FL, 33431.
Insiders trading at TherapeuticsMD Inc
Over the last 13 years, insiders at TherapeuticsMD Inc have traded over $21,656,853 worth of TherapeuticsMD Inc stock and bought 721,732 units worth $2,299,099 . The most active insiders traders include Cooper C. Collins, Brian Bernick oraz Robert G Finizio. On average, TherapeuticsMD Inc executives and independent directors trade stock every 29 days with the average trade being worth of $272,607. The most recent stock trade was executed by John C.K. Iv Milligan on 25 October 2019, trading 72,000 units of TXMD stock currently worth $198,000.
What does TherapeuticsMD Inc do?
therapeuticsmd, inc. is an innovative pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their health care issues. we create products to address the unique changes and challenges women experience through every stage of their lives. with momentum fueled by the needs of our customers, we combine entrepreneurial spirit and clinical expertise to develop innovative solutions designed to go beyond what is presently available. this includes a variety of therapies in our pipeline, along with prescription prenatal vitamins under the vitamedmd® and bocagreenmd® brands. see our community guidelines: https://www.therapeuticsmd.com/social-media-community-guidelines
What does TherapeuticsMD Inc's logo look like?
Complete history of Mr. Musing stock trades at iBio Inc, TherapeuticsMD oraz TherapeuticsMD Inc
TherapeuticsMD Inc executives and stock owners
TherapeuticsMD Inc executives and other stock owners filed with the SEC include:
-
John Milligan,
President, Secretary -
Brian Bernick,
Co-Founder -
Robert Finizio,
Chief Executive Officer and Director -
Robert G. Finizio,
Co-Founder & Vice Chair -
Mitchell Krassan,
Chief Strategy and Performance Officer -
John C. K. Milligan IV,
Chief Exec. Officer of VitaCare Prescription Services -
Michael Donegan,
Vice President - Finance -
Tommy Thompson,
Independent Chairman of the Board -
Cooper Collins,
Independent Director -
J. Martin Carroll,
Independent Director -
Angus Russell,
Independent Director -
Jules Musing,
Independent Director -
Dr. Brian A. Bernick,
Co-Founder & Chief Scientific Officer -
Nichol Ochsner,
Vice President, Investor Relations -
Gail Naughton,
Independent Director -
Karen Ling,
Independent Director -
Paul Bisaro,
Independent Director -
Bharat Warrier,
Chief Manufacturing Officer -
Sebastian Mirkin,
Chief Medical Officer -
Dawn Halkuff,
Chief Commercial Officer -
Marlan Walker,
General Counsel -
John Knighton,
Chief Compliance Officer -
Adam Miller,
Chief Information Officer -
James D'Arecca,
Chief Financial Officer -
Julia M. Amadio,
Chief Product Officer -
Mitchell L. Krassan,
Exec. VP and Chief Strategy & Performance Officer -
Chris Gish,
Sr. VP of Sales -
Michael Donegan,
Chief Accounting Officer & VP of Fin. -
James C. D'Arecca,
Chief Financial Officer -
Hugh O'Dowd M.B.A.,
Pres, CEO & Director -
Robert V Jr La Penta,
Director -
Nicholas Segal,
Director -
Jane F Barlow,
Director -
Daniel A Cartwright,
Chief Financial Officer -
Randall S Stanicky,
Director -
Samuel A Greco,
Director